Matthias Kromayer

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

MIG Verwaltungs AG is a private equity investment firm headquartered in Munich, Germany. It was founded in 2004 by entrepreneurs and financial institutions, to follow up on the success of the venture capital investment vehicles Global Chance Fund and Global Asset Fund, with which MIG's management had been involved.

ViroLogik GmbH develops drugs for treatment of viral diseases. It is developing a novel strategy to prevent formation of drug resistance in case of Hepatitis C and HIV infections. The company was founded in 2006 by Ulrich Schubert and is headquartered in Jena, Germany.

cerbomed GmbH manufactures and supplies medical devices for treating epilepsy. It offers NEMOS, a transcutaneous vagus nerve stimulation unit that treats epilepsy patients. The company was founded by Stefan Dietrich and Timo Freitag in 2005 and is headquartered in Erlangen, Germany.

BIOCRATES Life Sciences AG operates as a research and technology. It provides metabolic phenotyping services. The firm products are absoluteIDQ p150 kit, p180 kit, sterio17 kit, steroid reagents, biocrates bile acids kit, and steroid kit. The company was founded by Gunther Bonn, Adelbert Roscher, and Hartmut Glossmann in 2002 and is headquartered in Innsbruck, Austria.

AMSilk GmbH engages in the production of fiber and biopolymers.It offers implant coating, medical devices for OTC wound care, functional cosmetics, cell biology device kits, biosteel spidersilk fibers and spidersilk research license. It serves the biosteel fibers, medical devices, and cosmetic ingredients industry. The firm's materials are to be applied in numerous fields to improve existing products or to develop materials for completely new applications, which could not be realized until now due to the lack of an appropriate material. The company was founded by Axel H. Leimer, Thomas Scheibel, and Lin Römer in 2008 and is headquartered in Planegg, Germany.

Nexigen GmbH identifies and develops peptide based therapeutics for cancer. It focuses on the development of pathways to create transformative cancer therapies. The firm's technologies give access to drug targets which pose significant challenges to conventional discovery approaches. The company was founded by Annette Friebe, Burckhard Heil, and Claudia Carl in 2007 and is headquartered in Cologne, Germany.